Literature DB >> 20557855

Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) with two different capecitabine/oxaliplatin dosage regimens.

A Farkouh1, J Schueller, W Scheithauer, M Czejka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20557855     DOI： 10.5414/cpp48487

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN： 0946-1965            Impact factor:   1.366


× No keyword cloud information.
  2 in total

1.  Acute Reversible Heart Failure Caused by Coronary Vasoconstriction due to Continuous 5-Fluorouracil Combination Chemotherapy.

Authors:  Cornelia Dechant; Martina Baur; Rudolf Böck; Martin Czejka; Andrea Podczeck-Schweighofer; Christian Dittrich; Günter Christ
Journal:  Case Rep Oncol       Date:  2012-06-05

2.  Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer.

Authors:  Shigeyoshi Iwamoto; Hiromichi Maeda; Shoichi Hazama; Koji Oba; Naoko Okayama; Yutaka Suehiro; Takahiro Yamasaki; Nobuaki Suzuki; Hiroaki Nagano; Junichi Sakamoto; Hideyuki Mishima; Naoki Nagata
Journal:  J Cancer       Date:  2018-10-18       Impact factor: 4.207
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.